{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:20:06Z","timestamp":1783639206665,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-026-04334-8","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:15:21Z","timestamp":1778721321000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world treatment and healthcare resource utilization patterns among patients with advanced non-small cell lung cancer treated with amivantamab: a retrospective study using insurance claims data"],"prefix":"10.1186","volume":"26","author":[{"given":"David","family":"Waterhouse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Emond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Lafeuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexter","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"1","key":"4334_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"4334_CR2","doi-asserted-by":"publisher","first-page":"15009","DOI":"10.1038\/nrdp.2015.9","volume":"1","author":"C Gridelli","year":"2015","unstructured":"Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015;1:15009.","journal-title":"Nat Rev Dis Primers"},{"issue":"7689","key":"4334_CR3","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446\u201354.","journal-title":"Nature"},{"key":"4334_CR4","unstructured":"Noone AMHN, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER Cancer Statistics Review, 1975\u20132015, National Cancer Institute. April 2018 [Available from: Available from: https:\/\/seer.cancer.gov\/csr\/1975_2015\/"},{"key":"4334_CR5","unstructured":"American Cancer Society. Lung cancer survival rates June 27. 2025. Available from: https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/detection-diagnosis-staging\/survival-rates.html"},{"issue":"19","key":"4334_CR6","doi-asserted-by":"publisher","first-page":"6960","DOI":"10.3390\/jcm14196960","volume":"14","author":"YA Kariri","year":"2025","unstructured":"Kariri YA. Update on the treatment of non-small cell lung carcinoma (NSCLC). J Clin Med. 2025;14(19):6960.","journal-title":"J Clin Med"},{"key":"4334_CR7","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Cell Lung Cancer V.4.2025. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"10299","key":"4334_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535\u201354.","journal-title":"Lancet"},{"issue":"1","key":"4334_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","volume":"26","author":"B Melosky","year":"2022","unstructured":"Melosky B, Kambartel K, H\u00e4ntschel M, Bennetts M, Nickens DJ, Brinkmann J, et al. Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: A meta-analysis. Mol Diagn Ther. 2022;26(1):7\u201318.","journal-title":"Mol Diagn Ther"},{"issue":"10","key":"4334_CR10","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.jtho.2018.06.019","volume":"13","author":"JW Riess","year":"2018","unstructured":"Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, et al. Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. J Thorac Oncol. 2018;13(10):1560\u201368.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"4334_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11523-022-00868-z","volume":"17","author":"S Van Sanden","year":"2022","unstructured":"Van Sanden S, Murton M, Bobrowska A, Rahhali N, Sermon J, Rodrigues B, et al. Prevalence of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer in Europe: A pragmatic literature review and meta-analysis. Target Oncol. 2022;17(2):153\u201366.","journal-title":"Target Oncol"},{"issue":"4","key":"4334_CR12","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.21037\/tcr.2020.03.10","volume":"9","author":"F Wang","year":"2020","unstructured":"Wang F, Li C, Wu Q, Lu H. EGFR exon 20 insertion mutations in non-small cell lung cancer. Transl Cancer Res. 2020;9(4):2982\u201391.","journal-title":"Transl Cancer Res"},{"key":"4334_CR13","doi-asserted-by":"crossref","unstructured":"Marin-Acevedo JA, Pellini B, Kimbrough EO, Hicks JK, Chiappori A. Treatment strategies for non-small cell lung cancer with common EGFR mutations: A review of the history of EGFR TKIs approval and emerging data. Cancers (Basel). 2023;15(3);629.","DOI":"10.3390\/cancers15030629"},{"key":"4334_CR14","unstructured":"US Food and Drug Administration. FDA approves lazertinib with amivantamab-vmjw for non-small lung cancer August 19, 2024. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lazertinib-amivantamab-vmjw-non-small-lung-cancer"},{"key":"4334_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","volume":"4","author":"S Vyse","year":"2019","unstructured":"Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther. 2019;4:5.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"4334_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1158\/1535-7163.MCT-12-0620","volume":"12","author":"ME Arcila","year":"2013","unstructured":"Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013;12(2):220\u20139.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"4334_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/JTO.0b013e3182779d18","volume":"8","author":"GR Oxnard","year":"2013","unstructured":"Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8(2):179\u201384.","journal-title":"J Thorac Oncol"},{"key":"4334_CR18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.lungcan.2020.03.014","volume":"145","author":"G Yang","year":"2020","unstructured":"Yang G, Li J, Xu H, Yang Y, Yang L, Xu F, et al. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer. 2020;145:186\u201394.","journal-title":"Lung Cancer"},{"issue":"1","key":"4334_CR19","doi-asserted-by":"publisher","first-page":"18762","DOI":"10.1038\/s41598-021-98275-3","volume":"11","author":"C Morita","year":"2021","unstructured":"Morita C, Yoshida T, Shirasawa M, Masuda K, Matsumoto Y, Shinno Y, et al. Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions. Sci Rep. 2021;11(1):18762.","journal-title":"Sci Rep"},{"issue":"4","key":"4334_CR20","doi-asserted-by":"publisher","first-page":"S780","DOI":"10.1016\/S1556-0864(21)01995-X","volume":"16","author":"P Christopoulos","year":"2021","unstructured":"Christopoulos P, Groh\u00e9 C, Griesinger F, Falkenstern-Ge RF, Krisam J, Br\u00fcckner L, et al. 153P Real-world study of NSCLC with EGFR exon 20 insertions. J Thorac Oncol. 2021;16(4):S780\u201381.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"4334_CR21","doi-asserted-by":"publisher","first-page":"e620","DOI":"10.1016\/j.cllc.2019.06.018","volume":"20","author":"JY Wu","year":"2019","unstructured":"Wu JY, Yu CJ, Shih JY. Effectiveness of treatments for advanced non-small-cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations. Clin Lung Cancer. 2019;20(6):e620\u201330.","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"4334_CR22","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1016\/j.cllc.2021.07.001","volume":"23","author":"MP Shah","year":"2022","unstructured":"Shah MP, Aredo JV, Padda SK, Ramchandran KJ, Wakelee HA, Das MS, et al. EGFR exon 20 insertion NSCLC and response to platinum-based chemotherapy. Clin Lung Cancer. 2022;23(2):e148\u201353.","journal-title":"Clin Lung Cancer"},{"issue":"20","key":"4334_CR23","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.21037\/atm-20-6172","volume":"8","author":"Y Wang","year":"2020","unstructured":"Wang Y, Li J, Zhou Y, Cao S, Ling X, Zhang Y, et al. Tumor genomics and response to chemotherapy in advanced non-small cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations. Ann Transl Med. 2020;8(20):1297.","journal-title":"Ann Transl Med"},{"issue":"10","key":"4334_CR24","first-page":"100558","volume":"4","author":"SI Ou","year":"2023","unstructured":"Ou SI, Lin HM, Hong JL, Yin Y, Jin S, Lin J, et al. Real-world response and outcomes in patients with NSCLC with EGFR exon 20 insertion mutations. JTO Clin Res Rep. 2023;4(10):100558.","journal-title":"JTO Clin Res Rep"},{"key":"4334_CR25","doi-asserted-by":"publisher","first-page":"108548","DOI":"10.1016\/j.lungcan.2025.108548","volume":"203","author":"C Chouaid","year":"2025","unstructured":"Chouaid C, Bosquet L, Knott C, Li Z, Schaeffer M, Lin X, et al. Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study. Lung Cancer. 2025;203:108548.","journal-title":"Lung Cancer"},{"key":"4334_CR26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.lungcan.2021.10.020","volume":"162","author":"L Bazhenova","year":"2021","unstructured":"Bazhenova L, Minchom A, Viteri S, Bauml JM, Ou SI, Gadgeel SM, et al. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung Cancer. 2021;162:154\u201361.","journal-title":"Lung Cancer"},{"issue":"30","key":"4334_CR27","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/JCO.21.00662","volume":"39","author":"K Park","year":"2021","unstructured":"Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021;39(30):3391\u2013402.","journal-title":"J Clin Oncol"},{"key":"4334_CR28","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer May 21, 2021. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-amivantamab-vmjw-metastatic-non-small-cell-lung-cancer"},{"key":"4334_CR29","unstructured":"US Food and Drug Administration. FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications March 1, 2024. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-amivantamab-vmjw-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer-indications"},{"key":"4334_CR30","doi-asserted-by":"publisher","first-page":"635007","DOI":"10.3389\/fonc.2021.635007","volume":"11","author":"KKW To","year":"2021","unstructured":"To KKW, Fong W, Cho WCS. Immunotherapy in treating EGFR-mutant lung cancer: Current challenges and new strategies. Front Oncol. 2021;11:635007.","journal-title":"Front Oncol"},{"key":"4334_CR31","doi-asserted-by":"publisher","first-page":"102805","DOI":"10.1016\/j.ctrv.2024.102805","volume":"129","author":"AL D\u00e9sage","year":"2024","unstructured":"D\u00e9sage AL, Duruisseaux M, Lafitte C, Bayle-Bleuez S, Chouaid C, Fournel P, et al. Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature. Cancer Treat Rev. 2024;129:102805.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"4334_CR32","first-page":"100265","volume":"3","author":"D Fujimoto","year":"2022","unstructured":"Fujimoto D, Miura S, Yoshimura K, Wakuda K, Oya Y, Haratani K, et al. A real-world study on the effectiveness and safety of pembrolizumab Plus chemotherapy for nonsquamous NSCLC. JTO Clin Res Rep. 2022;3(2):100265.","journal-title":"JTO Clin Res Rep"},{"key":"4334_CR33","first-page":"100944","volume":"44","author":"A Spira","year":"2025","unstructured":"Spira A, Waters D, Ran T, Vadagam P, He J, Vanderpoel J, et al. Real-world treatment patterns of patients with EGFR exon 20 insertion-mutated advanced NSCLC treated with amivantamab or mobocertinib after platinum-based chemotherapy: A multi-database cohort study. Cancer Treat Res Commun. 2025;44:100944.","journal-title":"Cancer Treat Res Commun"},{"key":"4334_CR34","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.jval.2020.04.1531","volume":"23","author":"K Aguilar","year":"2020","unstructured":"Aguilar K, Boyd M, Davies K, Espirito J, Robert N. Concordance of real-world time-to-event endpoints with clinical outcomes in oncology studies. Value Health. 2020;23:S26.","journal-title":"Value Health"},{"key":"4334_CR35","first-page":"45","volume":"5","author":"B Walker","year":"2021","unstructured":"Walker B, Boyd M, Aguilar K, Davies K, Espirito J, Frytak J, et al. Comparisons of real-world time-to-event end points in oncology research. JCO Clin Cancer Inf. 2021;5:45\u20136.","journal-title":"JCO Clin Cancer Inf"},{"issue":"4","key":"4334_CR36","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s41669-023-00407-0","volume":"7","author":"J Vanderpoel","year":"2023","unstructured":"Vanderpoel J, Emond B, Ghelerter I, Milbers K, Lafeuille MH, Lefebvre P, et al. Healthcare resource utilization and costs in patients with EGFR-mutated advanced non-small cell lung cancer receiving first-line treatment in the United States: An insurance claims-based descriptive analysis. Pharmacoecon Open. 2023;7(4):617\u201326.","journal-title":"Pharmacoecon Open"},{"key":"4334_CR37","doi-asserted-by":"crossref","unstructured":"Waterhouse D, Lin I, Morrison L, Emond B, Lafeuille MH, Hilts A, et al. Healthcare resource use, healthcare costs, and unmet needs among patients treated for EGFR-mutated advanced or metastatic non-small cell lung cancer. J Health Econ Outcomes Res. 2025;12(2)98\u2013107.","DOI":"10.36469\/jheor.2025.142771"},{"key":"4334_CR38","unstructured":"US Food and Drug Administration. FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations September 19, 2024. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-amivantamab-vmjw-carboplatin-and-pemetrexed-non-small-cell-lung-cancer-egfr-exon-19"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04334-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04334-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04334-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:11:24Z","timestamp":1783638684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04334-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4334"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04334-8","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was considered exempt research under 45 CFR \u00a7 46.104(d)(4) as it involved only the secondary use of data that were de-identified in compliance with the Health Insurance Portability and Accountability Act (HIPAA), specifically, 45 CFR \u00a7 164.514.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"D. Waterhouse has received consultancy fees from Amgen, Astellas Pharma, AZTherapies, Bristol-Myers Squibb, Eisai, Fresenius Kbi, Gilead Sciences, Johnson & Johnson, Lilly, Merck, Mirati Therapeutics, Novartis, Pfizer, Regeneron\/Sanofi, Sanofi, and Takeda, and was on the speaker\u2019s bureau for Amgen, AZTherapies, Bristol-Myers Squibb, EMD Serono, Fresenius Kbi, Johnson & Johnson, and Merck. IL and D. Waters are employees of Johnson & Johnson and own stock\/stock options. LM, BE, YW, LD, and PL are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Johnson & Johnson, which funded the development and conduct of this study and manuscript. At the time of this study, MHL was an employee of Analysis Group, Inc., a consulting company that has provided paid consulting services to Johnson & Johnson, which funded the development and conduct of this study and manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"304"}}